Skip to content

Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study

Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05705999
Acronym
STOP-TIC
Enrollment
20
Registered
2023-01-31
Start date
2024-03-12
Completion date
2026-12-30
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tourette Syndrome

Keywords

Tourette Syndrome, Comprehensive Behavioral Intervention for Tics, Transcranial Magnetic Stimulation

Brief summary

This pilot study will investigate the clinical and neurophysiological effects of repetitive transcranial magnetic stimulation (rTMS) followed by comprehensive behavioral intervention for tics (CBIT) in adult patients with Tourette's Syndrome (TS). Two groups of moderate disease severity will be randomized to receive active or sham rTMS targeted to the supplementary motor area (SMA) followed by eight CBIT sessions. The change in tic frequency and severity (primary outcome) and neurophysiological changes (secondary outcome) will be compared between the two groups. The central hypothesis is that low frequency rTMS will augment the effects of CBIT through favorable priming of the SMA network.

Interventions

DEVICEtranscranial magnetic stimulation

The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% RMT. The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10-minute break in between each session

Sponsors

University of Florida
CollaboratorOTHER
Tourette Association of America
CollaboratorOTHER
West Virginia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older * Diagnosis of Tourette Syndrome * Moderate Tic Severity at baseline

Exclusion criteria

* Presence of metallic objects or neurostimulators in the brain * Pregnancy * History of active seizures or epilepsy * Contraindications to receiving fMRI * Inability to participate in CBIT due to other underlying cognitive or medical condition

Design outcomes

Primary

MeasureTime frameDescription
Yale Global Tic Severity Scale (YGTSS)Through study completion, an average of 3 monthsTic severity will be measured with YGTSS. YGTSS is a clinician-rated scale used to assess tic severity, scored out of 100 where a higher score indicates greater tic frequency and severity. It includes a checklist of motor and vocal tics followed by an assessment of the number, frequency, intensity, complexity, and inference of motor tics and phonic tics - scored separately. Each of these dimensions is scored on a 0 to 5 scale. The YGTSS provides three tic severity scores: Total Motor (0 to 25); Total Phonic (0 to 25) and the combined Total Tic Severity Score (0 to 50), as well as a separate Impairment dimension scored from 0 to 50.
Modified Rush Videotape Tic Rating Scale (mRVTRS)Through study completion, an average of 3 monthsThis is a tool used by an objective examiner to quantify the severity of a patient's tics by rating the number of body areas affected, motor tic frequency, phonic tic frequency, motor tic severity, and phonic tic severity, each on a 0 through 4 score by watching a video of the patient. Scored out of 20, where a higher score indicates greater tic severity.

Countries

United States

Contacts

Primary ContactJessica Frey, MD
Jessica.frey@hsc.wvu.edu304-598-6127

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026